Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study
European Journal of Cancer · 2026-06 · 241 · 116765
DOI: 10.1016/j.ejca.2026.116765 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Wenjia Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province 310053, China. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- School of Nursing, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province 310053, China.
- Department of Respiratory Medicine, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang Province 311200, China. Electronic address: wenjunli1028@163.com.
Zitieren
APA
Li, W., & Li, W. (2026). Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study. European Journal of Cancer, 241, 116765. https://doi.org/10.1016/j.ejca.2026.116765
Vancouver
Li W, Li W. Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study. European Journal of Cancer. 2026;241:116765. doi:10.1016/j.ejca.2026.116765
BibTeX
@article{Li2026,
author = {Li, Wenjia and Li, Wenjun},
title = {Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study},
journal = {European Journal of Cancer},
year = {2026},
volume = {241},
pages = {116765},
doi = {10.1016/j.ejca.2026.116765}
}
EUVIMED